MedTrace Logo

A Study of ATRA in the Treatment of ITP

NCT04618328 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-11-05

No results posted yet for this study

Summary

An open-label, multicenter study to compare the efficacy and safety of ATRA for the treatment of adults with primary immune thrombocytopenia (ITP)

Conditions

Interventions

DRUG

all trans retinoic acid

ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Navy General Hospital, Beijing

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiaohui Zhang, Doctor · Peking University People's Hospital, Peking University Insititute of Hematology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04618328 on ClinicalTrials.gov